Cargando…

A meta-analysis of the prognosis in patients with breast cancer with ipsilateral supraclavicular lymph node metastasis versus patients with stage IIIb/c or IV breast cancer

OBJECTIVE: To systematically evaluate the prognosis in patients with breast cancer with ipsilateral supraclavicular lymph node metastasis (SLNM) versus patients with stage IIIb/c or IV breast cancer, so as to provide evidence for clinical practice and research. METHODS: Computer retrieval from PubMe...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Xu-Hong, Zhang, Lei, Chen, Bo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: KeAi Publishing 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5643591/
https://www.ncbi.nlm.nih.gov/pubmed/29063013
http://dx.doi.org/10.1016/j.cdtm.2016.01.002
_version_ 1783271563840192512
author Liu, Xu-Hong
Zhang, Lei
Chen, Bo
author_facet Liu, Xu-Hong
Zhang, Lei
Chen, Bo
author_sort Liu, Xu-Hong
collection PubMed
description OBJECTIVE: To systematically evaluate the prognosis in patients with breast cancer with ipsilateral supraclavicular lymph node metastasis (SLNM) versus patients with stage IIIb/c or IV breast cancer, so as to provide evidence for clinical practice and research. METHODS: Computer retrieval from PubMed, Cochrane Libratory, CNKI (China National Knowledge Infrastructure), CBM and Wanfang Database with the assistance of other retrieval tools. All the studies evaluating the prognosis in patients with breast cancer with ipsilateral supraclavicular lymph node metastasis versus patients with stage IIIb/c or IV breast cancer were collected. Quality assessment was performed for the included data based on the quality assessment criteria appropriate for this study. Meta-analysis was performed using RevMan 5.3 software. RESULTS: A total of four references (1277 patients) were included. Assessment of influences on prognosis: As compared to the stage IIIb/c group, the 5-year survival rate was slightly lower in the SLNM group (relative risk (RR) 0.79; 95% confidence interval (CI) 0.59–1.06; Z = 1.55, P = 0.12), but there was no statistical significance; in contrast, the 5-year survival rate was significantly increased in the SLNM group as compared to the stage IV group (RR = 2.70; 95%CI: 1.36–5.37; Z = 2.84, P = 0.005). As compared to the stage IIIb/c group, the 5-year disease-free survival rate was lower in the SLNM group (RR = 0.65; 95%CI: 0.40–1.05; Z = 1.75, P = 0.08); however, there was no statistical significance. CONCLUSIONS: In patients with advanced breast cancer receiving combined therapy, the prognosis in patients with breast cancer with ipsilateral SLNM was significantly better than in those with stage IV breast cancer, and slightly worse than those with stage IIIb/c breast cancer. However, with the scarcity and poor quality of these observational studies, the long-term prognosis remains to be further verified in large-sample, high-quality studies.
format Online
Article
Text
id pubmed-5643591
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher KeAi Publishing
record_format MEDLINE/PubMed
spelling pubmed-56435912017-10-23 A meta-analysis of the prognosis in patients with breast cancer with ipsilateral supraclavicular lymph node metastasis versus patients with stage IIIb/c or IV breast cancer Liu, Xu-Hong Zhang, Lei Chen, Bo Chronic Dis Transl Med Review OBJECTIVE: To systematically evaluate the prognosis in patients with breast cancer with ipsilateral supraclavicular lymph node metastasis (SLNM) versus patients with stage IIIb/c or IV breast cancer, so as to provide evidence for clinical practice and research. METHODS: Computer retrieval from PubMed, Cochrane Libratory, CNKI (China National Knowledge Infrastructure), CBM and Wanfang Database with the assistance of other retrieval tools. All the studies evaluating the prognosis in patients with breast cancer with ipsilateral supraclavicular lymph node metastasis versus patients with stage IIIb/c or IV breast cancer were collected. Quality assessment was performed for the included data based on the quality assessment criteria appropriate for this study. Meta-analysis was performed using RevMan 5.3 software. RESULTS: A total of four references (1277 patients) were included. Assessment of influences on prognosis: As compared to the stage IIIb/c group, the 5-year survival rate was slightly lower in the SLNM group (relative risk (RR) 0.79; 95% confidence interval (CI) 0.59–1.06; Z = 1.55, P = 0.12), but there was no statistical significance; in contrast, the 5-year survival rate was significantly increased in the SLNM group as compared to the stage IV group (RR = 2.70; 95%CI: 1.36–5.37; Z = 2.84, P = 0.005). As compared to the stage IIIb/c group, the 5-year disease-free survival rate was lower in the SLNM group (RR = 0.65; 95%CI: 0.40–1.05; Z = 1.75, P = 0.08); however, there was no statistical significance. CONCLUSIONS: In patients with advanced breast cancer receiving combined therapy, the prognosis in patients with breast cancer with ipsilateral SLNM was significantly better than in those with stage IV breast cancer, and slightly worse than those with stage IIIb/c breast cancer. However, with the scarcity and poor quality of these observational studies, the long-term prognosis remains to be further verified in large-sample, high-quality studies. KeAi Publishing 2016-02-19 /pmc/articles/PMC5643591/ /pubmed/29063013 http://dx.doi.org/10.1016/j.cdtm.2016.01.002 Text en © 2016 Chinese Medical Association. Production and hosting by Elsevier B.V. on behalf of KeAi Communications Co., Ltd. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Review
Liu, Xu-Hong
Zhang, Lei
Chen, Bo
A meta-analysis of the prognosis in patients with breast cancer with ipsilateral supraclavicular lymph node metastasis versus patients with stage IIIb/c or IV breast cancer
title A meta-analysis of the prognosis in patients with breast cancer with ipsilateral supraclavicular lymph node metastasis versus patients with stage IIIb/c or IV breast cancer
title_full A meta-analysis of the prognosis in patients with breast cancer with ipsilateral supraclavicular lymph node metastasis versus patients with stage IIIb/c or IV breast cancer
title_fullStr A meta-analysis of the prognosis in patients with breast cancer with ipsilateral supraclavicular lymph node metastasis versus patients with stage IIIb/c or IV breast cancer
title_full_unstemmed A meta-analysis of the prognosis in patients with breast cancer with ipsilateral supraclavicular lymph node metastasis versus patients with stage IIIb/c or IV breast cancer
title_short A meta-analysis of the prognosis in patients with breast cancer with ipsilateral supraclavicular lymph node metastasis versus patients with stage IIIb/c or IV breast cancer
title_sort meta-analysis of the prognosis in patients with breast cancer with ipsilateral supraclavicular lymph node metastasis versus patients with stage iiib/c or iv breast cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5643591/
https://www.ncbi.nlm.nih.gov/pubmed/29063013
http://dx.doi.org/10.1016/j.cdtm.2016.01.002
work_keys_str_mv AT liuxuhong ametaanalysisoftheprognosisinpatientswithbreastcancerwithipsilateralsupraclavicularlymphnodemetastasisversuspatientswithstageiiibcorivbreastcancer
AT zhanglei ametaanalysisoftheprognosisinpatientswithbreastcancerwithipsilateralsupraclavicularlymphnodemetastasisversuspatientswithstageiiibcorivbreastcancer
AT chenbo ametaanalysisoftheprognosisinpatientswithbreastcancerwithipsilateralsupraclavicularlymphnodemetastasisversuspatientswithstageiiibcorivbreastcancer
AT liuxuhong metaanalysisoftheprognosisinpatientswithbreastcancerwithipsilateralsupraclavicularlymphnodemetastasisversuspatientswithstageiiibcorivbreastcancer
AT zhanglei metaanalysisoftheprognosisinpatientswithbreastcancerwithipsilateralsupraclavicularlymphnodemetastasisversuspatientswithstageiiibcorivbreastcancer
AT chenbo metaanalysisoftheprognosisinpatientswithbreastcancerwithipsilateralsupraclavicularlymphnodemetastasisversuspatientswithstageiiibcorivbreastcancer